Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Healthy
Interventions: Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo, Moxifloxacin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions: Ciprofloxacin 750 MG, Etoposide, Ciprofloxacin 1000 MG, Ciprofloxacin 500 mg; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Gonococcal Infection
Interventions: Azithromycin, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7527; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Dementia, Alzheimer's Disease
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 55 Years to 95 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 14
States / cities: Santa Ana, California • Hamden, Connecticut • Hialeah, Florida + 11 more

Conditions: Schizophrenia
Interventions: OPC-34712, Placebo, Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 16
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 12 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo, moxifloxacin, electrocardiogram (ECG); Drug · Procedure
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: HIV Infections
Interventions: Levofloxacin; Drug
Lead sponsor: R W Johnson Pharmaceutical Research Institute; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Bipolar Disorder
Interventions: Lithium or Valproate with placebo (PBO), Lithium or Valproate with Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 29
States / cities: Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more

Conditions: Bronchitis, Chronic
Interventions: placebo, azithromycin SR (Zithromax; compound: CP-62,993), levofloxacin; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 29
States / cities: Birmingham, Alabama • Columbiana, Alabama • Tallassee, Alabama + 21 more

Conditions: Healthy
Interventions: ALXN1840, Placebo, Moxifloxacin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Complicated Urinary Tract Infections
Interventions: Sulopenem, Sulopenem-Etzadroxil/Probenecid, Ertapenem, Ciprofloxacin, Amoxicillin-clavulanate; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 15
States / cities: Bellflower, California • Chula Vista, California • La Mesa, California + 11 more

Conditions: Schizophrenia
Interventions: PF-02545920, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 10
States / cities: Glendale, California • Lemon Grove, California • Paramount, California + 4 more

Conditions: Schizophrenia
Interventions: PF-00217830, Placebo, Aripiprazole; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Garden Grove, California • Torrance, California • Washington D.C., District of Columbia + 5 more

Conditions: Schizophrenia
Interventions: Aripiprazole; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: San Diego, California

Conditions: Contraception
Interventions: ortho tricyclen, Trinessa; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Healthy Subjects
Interventions: Vorasidenib 40 mg Oral Tablet, Ciprofloxacin 500 mg Oral Tablet, Vorasidenib 10 mg Oral Tablet; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Prostate Cancer, Urinary Tract Infection, Clostridium Difficile
Interventions: Ciprofloxacin; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy Volunteers
Interventions: ACP-196, Moxifloxacin 400 mg, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2409021, Placebo, Moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Bacterial Sinusitis
Interventions: cefdinir (Omnicef), levofloxacin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 23
States / cities: Birmingham, Alabama • Columbiana, Alabama • Eclectic, Alabama + 16 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
Interventions: Aripiprazole; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: SNS-595 Injection; Drug
Lead sponsor: Sunesis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Scottsdale, Arizona • Louisville, Kentucky • Durham, North Carolina + 1 more

Conditions: Corneal Ulcer, Eye Infections, Bacterial
Interventions: Antibiotics, Topical corticosteroid, Placebo; Drug
Lead sponsor: Thomas M. Lietman; Other
Eligibility: 16 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: San Francisco, California • Lebanon, New Hampshire

Conditions: Schizophrenia
Interventions: LY2140023, aripiprazole, olanzapine, risperidone; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more

Search by objective public record fields.

A Study of the Cardiac Effects of Danicopan in Healthy Adults

Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study

Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives

A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects

Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis

Abilify Therapy for Reducing Comorbid Substance Abuse

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

Steroids for Corneal Ulcers Trial

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients